All pages
Powered by GitBook
1 of 1

Global Expansion Strategy

Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.

2025-26: Domestic Market Expansion (South Korea)

  • Clinical validation with major hospitals, including:

    • Seoul National University Bundang Hospital

    • Inha University Hospital

    • Hanlim University Sacred Heart Hospital

  • Initial rollout in health screening centers with direct sales and platform partnerships.

  • AI-powered digestive health monitoring collaboration with Next Biomed & iKooB.

2025-26: Entry into the U.S. Market

  • Pilot program in Utah (Phase 2 region) before expanding to key medical hubs like New York, California, Boston, and Texas.

  • Strategic collaborations with top-tier U.S. institutions, including:

    • Harvard Medical School (MGH) – Two professors onboarding as advisors.

    • Oracle Healthcare – AI integration partnerships.

    • Medtronic – Exploring collaboration on medical AI devices.

  • Investment network expansion – Attracting U.S.-based investors to establish a sustainable market presence.

Japan Expansion

  • AI licensing to endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.

  • Partnership with CEC (Fujitsu subsidiary) to penetrate Japanese medical institutions.

  • Regulatory alignment for market approval and expansion into hospitals & screening centers.

Post-2027: Global Expansion

  • Following successful market entries in Korea, the U.S., and Japan, Apex AI will scale into Europe, China, and other high-demand regions.

  • Cloud-based AI diagnostics will drive accessibility, making Apex AI a global leader in AI-powered gastrointestinal cancer detection.